INT146355

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.51
First Reported 2006
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 15
Total Number 16
Disease Relevance 7.83
Pain Relevance 4.25

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleus (Aes)
Aes (Rattus norvegicus)
Pain Link Frequency Relevance Heat
headache 8 99.92 Very High Very High Very High
Ziconotide 240 99.26 Very High Very High Very High
abatacept 285 98.84 Very High Very High Very High
Pain 69 98.66 Very High Very High Very High
Infliximab 279 98.36 Very High Very High Very High
cva 5 96.96 Very High Very High Very High
analgesia 8 82.52 Quite High
Chronic nonmalignant pain 1 74.56 Quite High
Lamotrigine 4 74.24 Quite High
rheumatoid arthritis 52 67.08 Quite High
Disease Link Frequency Relevance Heat
Weight Loss 6 100.00 Very High Very High Very High
Headache 8 99.92 Very High Very High Very High
Fibrosarcoma 6 99.40 Very High Very High Very High
Dizziness 20 99.36 Very High Very High Very High
Amblyopia 3 98.92 Very High Very High Very High
Anxiety Disorder 8 98.84 Very High Very High Very High
Pain 78 98.66 Very High Very High Very High
Vomiting 26 98.04 Very High Very High Very High
Ocular Toxicity (including Many Sub-types) 9 97.72 Very High Very High Very High
Overactive Bladder 4 97.04 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
This diversity suggests that one single patient safety intervention is unlikely to effectively reduce all preventable AEs, especially since most quality improvement interventions have, at best, a modest impact on outcomes [17,18].
Negative_regulation (reduce) of AEs
1) Confidence 0.51 Published 2008 Journal BMC Health Serv Res Section Body Doc Link PMC2621200 Disease Relevance 0 Pain Relevance 0
The incidence AE rate was calculated as the number of AEs per ICU patient days.
Negative_regulation (number) of AEs
2) Confidence 0.37 Published 2008 Journal BMC Health Serv Res Section Body Doc Link PMC2621200 Disease Relevance 0.22 Pain Relevance 0
Nevertheless, the consistent findings strengthen our assertion that there is a need to find ways to reduce ICU-based AEs.
Negative_regulation (reduce) of AEs
3) Confidence 0.37 Published 2008 Journal BMC Health Serv Res Section Body Doc Link PMC2621200 Disease Relevance 0 Pain Relevance 0
Other outcomes such as pain, anxiety or functional status, which may be more sensitive to the effect of AEs and preventable AEs, might be more relevant to patients.
Negative_regulation (effect) of AEs associated with pain and anxiety disorder
4) Confidence 0.37 Published 2008 Journal BMC Health Serv Res Section Body Doc Link PMC2621200 Disease Relevance 0.28 Pain Relevance 0.17
Other outcomes such as pain, anxiety or functional status, which may be more sensitive to the effect of AEs and preventable AEs, might be more relevant to patients.
Negative_regulation (preventable) of AEs associated with pain and anxiety disorder
5) Confidence 0.37 Published 2008 Journal BMC Health Serv Res Section Body Doc Link PMC2621200 Disease Relevance 0.28 Pain Relevance 0.17
Other outcomes such as pain, anxiety or functional status, which may be more sensitive to the effect of AEs and preventable AEs, might be more relevant to patients.
Negative_regulation (effect) of AEs associated with pain and anxiety disorder
6) Confidence 0.37 Published 2008 Journal BMC Health Serv Res Section Body Doc Link PMC2621200 Disease Relevance 0.28 Pain Relevance 0.17
Secondary outcome measures were time to discontinuation due to AEs, prevalences and characteristics of AEs, decrease from baseline in pain intensity as measured on the NRS, and change in the Korean version of the Western Ontario and McMaster Universities (K-WOMAC) index score (scale: 0 = best to 100 = worst).
Negative_regulation (decrease) of AEs
7) Confidence 0.36 Published 2007 Journal Clin Ther Section Body Doc Link 17825689 Disease Relevance 0 Pain Relevance 0
Three patients (20.0%) experienced AEs, including weight loss, headache, and dizziness, which resolved with maintenance (Wallace 1998; Kothare et al 2004).
Negative_regulation (loss) of AEs associated with weight loss, dizziness and headache
8) Confidence 0.19 Published 2006 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2671817 Disease Relevance 1.33 Pain Relevance 0.14
0.001).38 During the initial titration phase, a significantly greater percentage of patients in the ziconotide group compared to the placebo group reported AEs, including abnormal gait, amblyopia, dizziness, nausea, nystagmus, pain, urinary retention, and vomiting.38
Negative_regulation (reported) of AEs associated with pain, ziconotide, vomiting, dizziness, overactive bladder, ocular toxicity (including many sub-types) and amblyopia
9) Confidence 0.19 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2710384 Disease Relevance 2.66 Pain Relevance 1.06
The types and numbers of AEs and overall safety profile were consistent with those reported for statin therapy (Knopp 1999; Schuster 2003).
Negative_regulation (numbers) of AEs
10) Confidence 0.11 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2663459 Disease Relevance 0.51 Pain Relevance 0
Overall, the frequency of AEs, related AEs and discontinuations due to AEs or SAEs was similar for the abatacept and placebo groups.
Negative_regulation (frequency) of AEs associated with abatacept
11) Confidence 0.07 Published 2008 Journal Annals of the Rheumatic Diseases Section Body Doc Link PMC2564802 Disease Relevance 0.36 Pain Relevance 0.84
Overall, the frequency of AEs, related AEs and discontinuations due to AEs or SAEs was similar for the abatacept and placebo groups.
Negative_regulation (frequency) of AEs associated with abatacept
12) Confidence 0.07 Published 2008 Journal Annals of the Rheumatic Diseases Section Body Doc Link PMC2564802 Disease Relevance 0.35 Pain Relevance 0.83
Overall, the frequency of AEs, related AEs and discontinuations due to AEs or SAEs was similar for the abatacept and placebo groups.
Negative_regulation (frequency) of AEs associated with abatacept
13) Confidence 0.07 Published 2008 Journal Annals of the Rheumatic Diseases Section Body Doc Link PMC2564802 Disease Relevance 0.36 Pain Relevance 0.83
In the first 3 days, the ZOL group had twice the number of AEs as compared to the RIS group (P < 0.001), and these were principally the flu-like symptoms, known to occur in association with the IV use of nitrogen-containing bisphosphonates (Table 2).
Negative_regulation (number) of AEs
14) Confidence 0.02 Published 2010 Journal Patient Prefer Adherence Section Body Doc Link PMC2915556 Disease Relevance 0.44 Pain Relevance 0.03
In the HORIZON-PFT study, the number of patients with AEs was significantly higher in the ZOL group (95.5% ZOL vs 93.9% placebo; P = 0.002), driven primarily by larger number of AEs associated with postdose symptoms.28 However, in the HORIZON-RFT study, the difference in the number of AEs between both groups was not significant (82.3% ZOL vs 80.6% placebo).43
Negative_regulation (number) of AEs
15) Confidence 0.02 Published 2010 Journal Patient Prefer Adherence Section Body Doc Link PMC2915556 Disease Relevance 0.41 Pain Relevance 0
Pemetrexed is associated with a further increase in overall survival of 0.14 years compared to the current standard of docetaxel in the predominantly non-squamous histology subgroup, and moreover shows considerable decrease in reported AEs.
Negative_regulation (decrease) of AEs
16) Confidence 0.02 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2841662 Disease Relevance 0.33 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox